Justin T. Brown, PhD
Principal Scientist, Asuragen
Clinical expectations for BCR-ABL monitoring have evolved over time both in response to more sensitive tests being developed and new treatments and management approaches emerging. Largely in response to these medical advances, many CML patients have been able to successfully manage their diseases over time, as evidenced through increasing long-term survival rates. Chronic management of an increasing population of CML patients, however, places unique pressure on supporting laboratories, requiring that testing become sensitive enough to support a broad spectrum of clinical decisions while also be scalable to accommodate an ever increasing number of tests.
In this webinar presentation, learn how the FDA-cleared QuantideX® qPCR BCR-ABL IS Kit can overcome these challenges, providing a simple, sensitive, and scalable approach to BCR-ABL monitoring that meets and exceeds today’s clinical expectations for testing.
